Skip to main content

Table 2 Prostein and tumor phenotype

From: Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities

   

Prostein immunostaining result

 
  

n

negative (%)

weak (%)

moderate (%)

strong (%)

P

Invasive breast carcinoma of no special type

pT1

774

95.9

3.5

0.6

0

0.2176

pT2

626

94.9

4.3

0.8

0

 

pT3-4

125

93.6

5.6

0

0.8

 

G1

191

96.3

3.1

0.5

0

0.0105

G2

817

96.9

2.7

0.4

0

 

G3

562

92.3

6.2

1.2

0.2

 

pN0

698

95.3

4.4

0.3

0

0.1691

pN+

527

94.7

4.2

1

0.2

 

pM0

198

96.5

3

0.5

0

0.5637

pM1

116

94.8

3.4

1.7

0

 

HER2 negative

889

96.4

3

0.6

0

0.0312

HER2 positive

124

91.9

4.8

3.2

0

 

ER negative

215

92.1

6

1.9

0

0.033

ER positive

746

96.5

2.8

0.7

0

 

PR negative

414

94.2

4.6

1.2

0

0.1836

PR positive

594

96.6

2.7

0.7

0

 

non-triple negative

786

95.8

3.2

1

0

0.5848

triple negative

144

94.4

4.9

0.7

0

 

Adenocarcinoma of the pancreas

pT1

16

75

18.8

6.3

0

0.7582

pT2

71

60.6

25.4

11.3

2.8

 

pT3

384

60.9

29.7

7.3

2.1

 

pT4

30

70

16.7

10

3.3

 

G1

17

52.9

35.3

11.8

0

0.7482

G2

353

61.8

28

7.4

2.8

 

G3

108

62

30.6

6.5

0.9

 

pN0

108

58.3

24.1

14.8

2.8

0.0424

pN+

392

62.5

29.3

6.1

2

 

R0

253

62.1

26.1

9.1

2.8

0.5101

R1

208

63

27.9

8.2

1

 

MMR proficient

453

61.8

28

7.7

2.4

0.8875

MMR deficient

3

66.7

33.3

0

0

 

Adenocarcinoma of the stomach

pT1-2

63

84.1

9.5

6.3

0

0.4894

pT3

126

85.7

11.1

3.2

0

 

pT4

126

84.9

13.5

1.6

0

 

pN0

86

87.2

9.3

3.5

0

0.8345

pN+

223

86.1

10.8

3.2

0.0

 

MMR proficient

40

70

15

15

0

0.0015

MMR deficient

259

85.7

12.7

1.5

0

 

Adenocarcinoma of the colon

pT1

80

78.8

18.8

1.3

1.3

0.0061

pT2

414

70.5

25.6

3.1

0.7

 

pT3

1195

81.1

15.6

2.9

0.4

 

pT4

416

79.1

17.8

2.4

0.7

 

pN0

1101

77.7

17.9

3.7

0.6

0.0608

pN+

993

79.5

18.2

1.8

0.5

 

V0

1514

77.8

18.1

3.4

0.7

0.0139

V1

546

81.3

17.2

1.3

0.2

 

L0

684

80

15.8

3.7

0.6

0.1454

L1

1387

78.1

19

2.4

0.6

 

right side

452

75.4

19.5

3.8

1.3

0.0479

left side

1187

80.5

16.7

2.4

0.4

 

MMR proficient

1104

79.3

17.7

2.4

0.6

0.5061

MMR deficient

85

77.6

17.6

4.7

0

 

RAS wildtype

422

85.5

12.8

1.4

0.2

0.0133

RAS mutation

328

77.4

17.7

4

0.9

 

BRAF wildtype

123

79.7

16.3

1.6

2.4

0.6308

BRAF V600E mutation

16

75

12.5

6.3

6.3

 
  1. Abbreviation: pT Pathological tumor stage, G Grade, pN Pathological lymph node status, pM Pathological status of distant metastasis, R Resection margin status, V Venous invasion, L Lymphatic invasion, PR Progesteron receptor, MMR Mismatch repair, ER Estrogen receptor